Quarterly Period Covered: Third quarter of fiscal year 2026 (nine months ended July 31, 2026), filed September 1, 2026 Company Overview: Laboratory analytical instruments manufacturer (SIC 3826) headquartered in Santa Clara, California, with fiscal year ending October 31 Financial Statements Included: Unaudited condensed consolidated balance sheets, statements of income, comprehensive income,…

Our analysis rates this filing NEUTRAL. Agilent Technologies presents a balanced risk profile with moderate concerns centered on the recent Biocare acquisition. The three identified risks (integration execution, increased leverage, and FX exposure) are typical for a company executing a material M&A…

Concern level: ELEVATED (5.2/10). Key factors: Biocare acquisition integration risk (severity 6/10) - Recent June 2026 acquisition introduces execution risk, goodwill impairment potential, and customer/employee retention challenges if synergies not realized; Increased leverage from acquisition financing - Senior Notes 2032 issuance constrains financial flexibility and increases debt service…

Notable risk changes: Biocare acquisition completed June 24, 2026 - introduces integration execution risk and potential for goodwill impairment if synergies not achieved; Senior Notes 2032 issued June 25, 2026 - increased leverage from acquisition financing reduces financial flexibility and increases debt service obligations; Geographic revenue exposure across Americas, Europe, and Asia-Pacific with derivative…

The model predicts A will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.